Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,967.38
(
1.18%
)
US TECH 100
25,156.80
(
1.87%
)
Dow Jones
48,535.99
(
0.66%
)
Brent Oil
92.40
(
-3.21%
)
Bitcoin
73,983.28
(
-0.29%
)
News Focus
News Focus
Post# of 821337
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

LearningEveryTrade

Send PM Follow Ignore
Followers 21
Posts 1402
Boards Moderated 0
Alias Born 03/03/2021

LearningEveryTrade

Re: hmuney post# 459871

Friday, 04/15/2022 9:24:48 AM

Friday, April 15, 2022 9:24:48 AM

Post# of 821337
Sweet, 'but' LL session is " Unique Challenges in Emerging Immunotherapies"... so, let's repeat, "challenges"... Don't fall for TLD assumption based on a discussions about challenges of something we are begging for...

I am super hopeful we can glean something new, but it certainly could be combo trial based info, or that outside of our NWBO universe, DC vaccines are not understood or accepted yet, hence Bosch's ASCO's title.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent NWBO News
More NWBO News